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Abstract: Evaluation of relationships between molecular modeling structural parameters 
and high-performance liquid chromatography (HPLC) retention data of 11 cardiovascular 
system drugs by principal component analysis (PCA) in relation to their pharmacological 
activity was performed. The six retention data parameters were determined on three 
different HPLC columns (Nucleosil C18 AB with octadecylsilica stationary phase, IAM 
PC C10/C3 with chemically bounded phosphatidylcholine, and Nucleosil 100-5 OH with 
chemically bounded propanodiole), and using isocratically acetonitrile: Britton-Robinson 
buffer as the mobile phase. Additionally, molecular modeling studies were performed with 
the use of HyperChem software and MM+ molecular mechanics with the semi-empirical 
AM1 method deriving 20 structural descriptors. Factor analysis obtained with the use of 
various sets of parameters:  structural parameters, HPLC retention data, and all  26 
considered parameters,  led to the  extraction of  two main factors. The first principal 
component (factor 1) accounted for 44-57% of the variance in the data. The second 
principal component (factor 2) explained 29-33% of data variance. Moreover, the total data 
variance explained by the first two factors was at the level of 73-90%. More importantly, 
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the PCA analysis of the HPLC retention data and structural parameters allows the 
segregation of  circulatory system drugs according to their pharmacological 
(cardiovascular) properties as shown by the distribution of the individual drugs on the 
plane determined by the two principal components (factors 1 and 2). 
Keywords:  high-performance liquid chromatography (HPLC); cardiovascular system 
drugs; principal component analysis (PCA); molecular modeling parameters 
 
1. Introduction  
The cardiovascular system, which distributes blood and provides the nutrients the system needs to 
keep the heart pumping, is a closed system (meaning that the blood never leaves the network of 
arteries, veins and capillaries), The main components of this system are the heart, the blood, and the 
blood vessels [1].  
Cardiovascular (cardiac) pharmaceutical agents are divided in  groups of drugs  such  as 
antiarrhythmic agents,  ACE inhibitors,  angiotensin II receptor antagonists,  beta blocker,  calcium 
channel blocker, and drugs with blood vassels activity [1-3]. The antiarrhythmic  group of 
pharmaceuticals agents are used to suppress fast rhythms of the heart (cardiac arrhythmias), such as 
atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. There are five main 
classes of antiarrhythmic agents proposed by Vaughan Williams (VW): class I agents interfere with the 
sodium (Na
+) channel, divided additionally into subclass Ia-c (drugs such as dispyramide, quinidine, 
phenytoine, propaphenone, etc.), class II consists of anti-sympathetic nervous system agents with most 
agents in this class functioning  as  beta blockers  (e.g.,  metopropolol,  etc.),  class III  agents affect 
potassium (K
+) efflux (e.g., amidarone, sotalol, etc.), class IV agents affect calcium (Ca
2+) channels 
(e.g., diltiazem, verapamil, etc.), and class V agents work by other or unknown mechanisms (drugs 
such  as adenosine, digoxin,  etc.). This classification is based on the primary mechanism of 
antiarrhythmic effect. However, some of antiarrhythmic agents (for example,  amiodarone) have 
multiple mechanisms of action [1,2,4-6]. The group of ACE inhibitors (angiotensin-converting enzyme 
inhibitors) is a group of pharmaceuticals (compounds such as captopril, perindopril, etc.) that are used 
primarily in the treatment of hypertension and congestive heart failure, and in some cases as the drugs 
of first choice. Generally, ACE inhibitors block the conversion of angiotensin I to angiotensin II, and 
consequently lower arteriolar resistance and increase venous capacity, increase cardiac output and 
cardiac index, lower renovascular resistance, and increase natriuresis  [1,7].  On the other hand, 
angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), are a group 
of pharmaceuticals (drugs such as candesartan, irbesartan, etc.) that modulate the renin-angiotensin-
aldosterone system. They block the activation of angiotensin II receptors via block of AT1 receptors, 
causing  vasodilation,  reduced  of secretion of vasopressin,  reduced  production and secretion of 
aldosterone, and reduction of blood pressure. Their main use is in hypertension (high blood pressure), 
diabetic nephropathy  (kidney damage due to diabetes) and  congestive heart failure. Moreover, 
angiotensin II receptor antagonists are primarily used for the treatment of hypertension  when  the 
patient is intolerant to ACE inhibitor therapy [1,8]. The beta blockers (β-blockers) is a class of drugs Int. J. Mol. Sci. 2010, 11                       
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(compounds  such  as acebutolol, atenolol, carvedilol, nadolol, butaxamine,  etc.) used for various 
indications, but particularly for the management of cardiac arrhythmias, cardioprotection after 
myocardial infarction (heart attack), and hypertension. There are three known types of beta receptor, 
designated β1, β2 and β3 [1,9]. The calcium channel blockers (CCBs) are a class of drugs and natural 
substances (compounds such as amlodipine, verapamil, diltiazem, etc.) that disrupt the calcium (Ca
2+) 
conduction of calcium channels, and have effects on many cells such as cardiac muscle, i.e., heart, 
smooth muscles of blood vessels, or neurons. They main clinical usage is to decrease blood pressure. 
Additionally, the calcium channel blockers are further  divided  into  some classes such  as 
dihydropyridine, phenylalkylamine or benzothiazepine calcium channel blockers. The dihydropyridine 
calcium channel blockers (drugs as amlodipine, nifedipine, nimodipine, nisoldipine, nitrendipine and 
others) are often used to reduce systemic vascular resistance and arterial pressure, but are not used to 
treat angina because the vasodilation and hypotension can lead to reflex tachycardia, compared to 
phenylalkylamine calcium channel blockers (drugs such as verapamil and others) which are relatively 
selective for myocardium, reduce myocardial oxygen demand and reverse coronary vasospasm, and 
are often used to treat angina. They also have minimal vasodilatory effects compared with 
dihydropyridines and therefore cause less reflex tachycardia, making it appealing for treatment of 
angina. However, the class of benzothiazepine calcium channel blockers (drugs such as diltiazem, etc.) 
is an intermediate class between phenylalkylamine and dihydropyridines in their selectivity for 
vascular calcium channels. Moreover, by having both cardiac depressant and vasodilator actions, 
benzothiazepines are able to reduce arterial pressure without producing the same degree of reflex 
cardiac stimulation caused by dihydropyridines [1,9-12]. On the other hand, the drugs with blood 
vassels activity (compounds such as pentoxphylline, etc.) improve blood flow through blood vessels 
and therefore help with blood circulation in the arms and legs, and  also help to  prevent stroke,   
can be used in managing sickle cell disease and improve blood flow to the brain. They are also used to 
treat intermittent claudication resulting from obstructed arteries in the limbs, and vascular   
dementia [1,13-15]. 
Principal component analysis (PCA) is a  method  intending to extract and visualize systematic 
patterns or trends in large data matrices. By PCA, one can reduce the number of variables in a data set 
by finding linear combinations of variables explaining most of the variability. It is known that the 
independent variables in multiple regression analysis are often mutually inter-correlated and therefore 
are inappropriate for that kind of analysis. On the other hand, such variables can be subjected to 
multivariate analysis, as for example PCA or factor analysis. By PCA, all those original parameters 
which are interrelated by simple or multiple correlations can be combined in a linear manner to the 
limited number of orthogonal principal components (factors) [16]. The PCA method as so far was used 
for the pharmacological classification of a large set of drugs based on HPLC retention data [17-21]. 
Recently, PCA of HPLC retention data in combination with molecular modeling structural parameters 
found a wide application in QSAR analysis for pharmacological classification of drugs [22]. 
The goal of the present study was to determine the relationships between HPLC retention 
parameters of a series of compounds differing in chemical structure and characterized by cardiac 
pharmacological activity and their structural parameters obtained by molecular modeling calculations 
applying the PCA method. The following 11 cardiovascular system drugs were selected for  the Int. J. Mol. Sci. 2010, 11                       
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proposed studies:  amiodarone,  amlodipine, nifedipine, nimodipine, nisoldipine, nitrendipine, 
verapamil, diltiazem, disopyramide, propaphenone and pentoxyphylline. 
2. Results and Discussion 
The chemical structures of the studied compounds and their pharmacological classification are 
presented in Figure  1 and Table 1, respectively.  The values of six  HPLC retention parameters 
(Nucleosil C18 2.5-  Nucleosil OH 7.0) and 20 structural parameters (TE-P) for the  considered 
compounds are presented in Table 2. Factor analysis led to the extraction of four, three or five main 
factors with eigenvalue higher than 1 from the analyzed group of parameters: structural parameters, 
HPLC retention data and all parameters, respectively (for results see Table 3). In the set of structural 
parameters, the first factor accounted for 46% of the data variance and the second one for 29%. On the 
other hand, in the set of HPLC retention data and all 26 analyzed parameters, the first factor accounted 
for 57% and 44% of the data variance, respectively, and second one for 33% and 29%, respectively. 
These data indicate that the majority of the information contained in the original data matrix can be 
explained by two principal components and it can be interpreted that two principal components contain 
the significance part of information held previously in original molecular descriptors (about 75% of 
information), HPLC retention (about 90% of information) or altogether HPLC and molecular 
properties variables (about 73% of information). Additionally, the results of factor analysis that 
represent the first two loadings (factors 1 and 2) of each variables and their two-dimensional scatter 
plots obtained with the use of various sets of parameters (structural parameters, HPLC retention data, 
and all 26 parameters from structural parameters and HPLC retention data) were collected in Table 4 
and Figure 2a, Table 5 and Figure 2b, and Table 6 and Figure 2c, respectively. The highest factor 
loadings among the variables over 0.7 were presented in bold type. Moreover, in the set of structural 
parameters (Figure 2a) the factor 1 depended mostly on total energy (TE), binding energy (BE), atom 
interaction energy (IAE), electronic energy (EE), core-core interaction energy (ECC), surface area of 
the molecule available for solvent (SA), volume of molecule (V), refraction (R), polarizability (P), 
whereas factor 2 depended mostly on heat of formation (HF), lowest unoccupied molecular orbital 
energy (ELUMO), the “hardness” of molecules (HARD), the value of the highest positive charge of 
atoms that constitute a molecule (MAX_POS), the difference between the highest positive and 
negative charges of atoms constituting a molecule (DELTA), and the logarithm of the n-octanol-water 
partition coefficient (LOG_P). The presented data are in accordance with our previous results [22] 
obtained for some antipyretic, anti-inflammatory and analgesic  drugs, and showed that factor 1 
presented mainly properties connected with molecular (size) bulkiness (like SA, V, R, P or TE), 
whereas factor 2 presented properties related to electronic propertied (like ELUMO, MAX_POS, or 
DELTA). Int. J. Mol. Sci. 2010, 11                       
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Figure 1. Chemical structures of the 11 studied compounds. 
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In the case of the HPLC retention dataset (Figure 2b), factor 1 depended on log k parameters 
obtained on columns packed with stationary phases other than octadecylsilica such as IAM PC C10/C3 
column  with chemically bounded phosphatidylcholine and Nucleosil 100-5 OH  with chemically 
bounded  propanodiole  at both 2.5 and 7.0 pH. On the other hand, factor 2 depended on log kw 
parameters obtained on a Nucleosil C18 AB column packed with octadecylsilica also at both 2.5 and 
7.0 pH. However, these results are contrary to data obtained for some antipyretic, anti-inflammatory 
and analgesic drugs [22], which showed that factor 1 depended mostly on chromatographically data 
(log kw) obtained only on a Nucleosil C18 AB column, whereas factor 2 depended mainly on log kw 
parameters obtained on columns packed with stationary phases other than octadecylsilica. 
Table 1. The classification of the 11 studied cardiovascular system drugs according to their 
pharmacological activity. 
Compound 
Antiarrhythmic activity 
a 
Lack of 
anti-
arrhythmi
c activity 
b 
Blood 
vassels 
activity 
c 
Anti 
hyper-
tension 
activity 
d 
Receptor  Chanel blockers 
 
M2 
muscarinic 
antagonist 
α-
receptors 
Na
+ class I 
K
+  
class III
 
Ca
2+ 
class 
IV 
Ca
2+ 
Ia  Ic 
amiodarone  -  +  -  -  +  -  -  -  + 
amlodipine  -  -  -  -  -  -  +  -  + 
diltiazem  -  -  -  -  -  +  -  -  + 
disopyramide  +  -  +  -  -  -  -  -  + 
nifedipine  -  -  -  -  -  -  +  -  + 
nimodipine  -  -  -  -  -  -  +  -  + 
nisoldipine  -  -  -  -  -  -  +  -  + 
nitrendipine  -  -  -  -  -  -  +  -  + 
pentoxyphylline  -  -  -  -  -  -  -  +  - 
propaphenone  -  -  -  +  -  -  -  -  + 
verapamil  -  +  -  -  -  +  -  -  + 
a  data from [1-4];  
b  data from [1,2,9,11,28-34];  
c  data from [1,2,35-43];  
d  data from [1,2,44-46].  
Antiarrhythmic activity, blood vassels activity and antihypertension activity are presented as positive (+) 
or negative (-). 
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Table 2. Values of HPLC retention data and molecular descriptors used in principal component analysis (PCA). See Materials and methods 
for HPLC column characteristics and definitions of molecular parameters. 
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1  2.51  4.32  -0.19  1.82  -0.41  0.99  -125943  -6134  -119809  -1014808  888865  -8.1  -9.2  -0.81  -5.0  -4.2  -0.30  0.34  0.64  2.61  792  1385  -1.4  6.57  144  56 
2  1.75  2.31  -0.49  1.23  -0.44  0.77  -122106  -5447  -116660  -986416  864310  -173.6  -8.8  -0.38  -4.6  -4.2  -0.40  0.36  0.76  4.99  635  1123  -8.6  -0.01  109  42 
3  1.37  2.25  -0.58  0.40  -0.44  0.67  -116762  -5719  -111043  -975452  858691  -73.8  -8.6  -0.40  -4.5  -4.1  -0.37  0.30  0.67  1.15  660  1155  -4.7  2.4  114  45 
4  0.60  1.59  0.17  0.61  -0.44  0.65  -92905  -5482  -87423  -793186  700281  16.3  -8.9  -0.10  -4.5  -4.4  -0.43  0.31  0.74  2.31  586  1041  -3.6  3.99  102  41 
5  2.14  2.22  0.07  0.03  0.22  0.26  -109704  -4536  -105168  -816705  707002  -109.6  -9.0  -0.61  -4.8  -4.2  -0.35  0.36  0.71  9.67  545  939  -6.7  -3.48  91  34 
6  2.62  2.69  0.14  0.09  0.22  0.31  -131466  -5762  -125704  -1089747  958282  -175.4  -9.1  -0.88  -5.0  -4.1  -0.39  0.57  0.95  7.11  652  1154  -7.7  -2.89  112  42 
7  2.77  2.86  0.23  0.17  0.23  0.32  -120482  -5379  -115103  -991599  871116  -127.8  -9.0  -0.69  -4.9  -4.2  -0.38  0.57  0.95  8.38  600  1062  -3.9  -2.27  105  40 
8  2.40  2.51  0.17  0.12  0.23  0.31  -113306  -4827  -108480  -856446  743139  -125.3  -9.1  -0.82  -5.0  -4.1  -0.38  0.57  0.95  7.18  570  981  -7.0  -3.14  96  36 
9  0.56  0.57  -0.13  -0.15  0.22  0.24  -85329  -3839  -81490  -550132  464803  -49.2  -9.0  -0.36  -4.7  -4.3  -0.36  0.41  0.77  4.44  515  837  -1.2  -0.14  74  28 
10  1.68  2.17  -0.53  1.12  -0.43  0.74  -97523  -5382  -92141  -768876  671353  -95.0  -9.3  -0.36  -4.8  -4.5  -0.31  0.28  0.59  4.72  589  1050  -5.4  3.4  100  39 
11  1.79  2.15  -0.58  0.61  -0.43  0.68  -130850  -7144  -123706  -1123270  992420  -85.9  -8.5  0.12  -4.2  -4.2  -0.26  0.15  0.41  4.69  798  1394  -7.6  5.05  133  58 
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Table 3. Summary  of  the  results of principal component analysis derived for the 
compounds studied. 
No. 
of 
factor 
Structural parameters 
a  HPLC retention data 
b  All data 
c 
Eigen-
value 
Variance 
explained 
(%) 
Total 
variance 
explained 
(%) 
Eigen-
value 
Variance 
explained 
(%) 
Total 
variance 
explained 
(%) 
Eigen-
value 
Variance 
explained 
(%) 
Total 
variance 
explained 
(%) 
1  9.24  46.18  46.18  3.42  56.92  56.92  11.34  43.60  43.60 
2  5.82  29.10  75.27  1.98  33.08  90.00  7.59  29.21  72.81 
3  2.41  12.07  87.34  0.46  7.61  97.61  3.20  12.30  85.11 
4  1.16  5.81  93.15  0.10  1.67  99.28  1.34  5.16  90.27 
5  0.74  3.68  96.83  -  -  -  1.16  4.46  94.73 
6  -  -  -  -  -  -  0.74  2.86  97.59 
a PCA performed only for structural parameters; 
b PCA performed only for HPLC retention 
data; 
c PCA performed for structural parameters along with HPLC retention data. 
 
Table 4. Principal component analysis loadings by structural parameters. 
Structural parameters  Factor 1  Factor 2 
TE  0.7651  -0.6392 
BE  0.9569  0.0165 
AIE  0.7404  -0.6655 
EE  0.8450  -0.4976 
ECC  -0.8492  0.4809 
HF  -0.0313  -0.7792 
EHOMO  -0.4810  -0.2329 
ELUMO  -0.2627  -0.7643 
EN  -0.3883  -0.5919 
HARD  -0.3389  0.7326 
MAX_NEG  -0.5966  -0.2413 
MAX_POS  0.4951  0.7760 
DELTA  0.5749  0.7005 
TDM  0.3436  0.6671 
SA  -0.9666  -0.0155 
V  -0.9749  0.0133 
HE  0.2474  -0.4908 
LOG_P  -0.5978  -0.7178 
R  -0.9384  0.0650 
P  -0.9750  -0.0713 
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Table 5. Principal component analysis loadings by HPLC retention data. 
HPLC retention data  Factor 1  Factor 2 
Nucleosil C18 2.5  -0.0666  -0.9490 
Nucleosil C18 7.0  0.4324  -0.8885 
IAM 2.5  -0.7218  -0.3973 
IAM 7.0  0.9270  -0.2296 
Nucleosil OH 2.5  -0.9296  -0.2897 
Nucleosil OH 7.0  0.9896  -0.0226 
 
Table 6. Principal component analysis loadings by all data. 
All data  Factor 1  Factor 2 
Nucleosil C18 2.5  -0.2015  -0.9114 
Nucleosil C18 7.0  -0.5561  -0.6065 
IAM 2.5  0.6107  -0.4332 
IAM 7.0  -0.7057  0.1657 
Nucleosil OH 2.5  0.7475  -0.5362 
Nucleosil OH 7.0  -0.8065  0.3277 
TE  0.6488  0.7362 
BE  0.9308  0.1287 
AIE  0.6210  0.7579 
EE  0.7461  0.6032 
ECC  -0.7525  -0.5869 
HF  -0.1472  0.6855 
EHOMO  -0.4196  0.2353 
ELUMO  -0.3112  0.7591 
EN  -0.3914  0.5898 
HARD  -0.1857  -0.7573 
MAX_NEG  -0.6159  0.0915 
MAX_POS  0.5959  -0.7068 
DELTA  0.6618  -0.5966 
TDM  0.4756  -0.6349 
SA  -0.9554  -0.1519 
V  -0.9681  -0.1769 
HE  0.1498  0.4308 
LOG_P  -0.7316  0.5915 
R  -0.9413  -0.2332 
P  -0.9753  -0.0994 
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Figure 2. Two-dimensional scatter plots of the loadings of the first two factors: a) by 
structural parameters, b) by HPLC retention data, c) by structural parameters along with 
HPLC retention data. 
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In the dataset including all parameters (Figure 2c),  factor 1 depended mostly on log k values 
obtained on IAM PC C10/C3 column only at pH 7.0 and on Nucleosil 100-5 OH column at both pH 
2.5 and 7.0 in the set of HPLC retention parameters, and on binding energy (BE), electron energy 
(EE), core-core interaction energy (ECC), surface area of the molecule available for solvent (SA), 
volume of molecule (V), logarithm of the n-octanol-water partition coefficient (LOG_P), refraction (R) 
and polarizability (P) in the set of molecular parameters. It is evident that these parameters reflect the 
size (bulkiness) of compounds studied, and condenses mainly information about their molecular size. 
On the other hand, the factor 2 depended mostly on log kw value obtained on Nucleosil C18 AB 
column only at pH 2.5 in the set of HPLC retention parameters, and on total energy (TE), atom 
interaction energy (IAE), lowest unoccupied molecular orbital energy (ELUMO), the “hardness” of 
molecules (HARD) and the value of the highest positive charge of atoms that constitute a molecule 
(MAX_POS) in the set of molecular parameters. In this case, factor 2 presented properties related to 
electronic properties rather than their bulkiness. 
Almost all the information (total data variance at the level 73-90%) can be explained by the first 
two principal components. Therefore, specific compounds can be compared on the basis of two 
principal component scores (objects) plots. Principal component scores calculated for all studied 
compounds and their individual positions on the plane determined by the two factor axes and 
performed only for structural parameters, only for HPLC retention data, and for all structural and 
HPLC retention data  parameters  together  are presented in Table 7,  and Figure 3a-c, respectively. 
Moreover, most of the studied compounds possess various pharmacological properties (antiarrhythmic 
or non- antiarrhythmic activity, blood vassels activity, or antihypertension activity), and their activities 
in all these aspects should be estimated in the same conditions. However, the classification of studied 
cardiovascular system drugs according to their pharmacological properties based on literature data is 
presented in Table 1. 
Table 7. Principal component analysis scores of the studied compounds. 
Compound 
Structural 
parameters 
a 
HPLC retention 
data 
b  All data 
c 
No.  Name  Factor 1  Factor 2  Factor 1  Factor 2  Factor 1  Factor 2 
1  amiodarone  -1.1793  -0.1644  1.5754  -1.5335  -1.4266  -0.2749 
2  amlodipine  -0.2667  0.4491  1.0088  0.2542  -0.4023  -0.1355 
3  diltiazem   -0.5703  -0.3440  0.5879  0.7398  -0.5999  0.4120 
4  disopyramide  0.4344  -1.3892  0.1143  1.0613  0.2651  1.4139 
5  nifedipine  0.7363  0.3826  -0.9964  -0.3150  0.8611  -0.3602 
6  nimodipine  -0.1657  1.7114  -0.9049  -0.9047  0.1784  -1.6478 
7  nisoldipine  0.2700  1.0449  -0.8930  -1.1573  0.4737  -1.1303 
8  nitrendipine  0.7518  1.0173  -0.9329  -0.7018  0.8768  -0.9184 
9  pentoxyphylline  1.6061  -1.0869  -1.1599  1.6600  1.5499  1.3053 
10  propaphenone  0.4022  -0.9245  0.9337  0.4110  0.0136  0.9640 
11  verapamil  -2.0187  -0.6963  0.6671  0.4860  -1.7899  0.3719 
a PCA performed only for structural parameters; 
b PCA performed only for HPLC retention data;  
c PCA performed for structural parameters along with HPLC retention data. 
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Figure 3a presents the positions of particular compounds on the plane determined by factors 1 and 2 
obtained for structural parameters, and is characterized by an arrangement of three clusters. The first 
cluster  contains  disopyramide and propaphenone with about a  value  of  0.5 of factor 1 and with 
negative values of factor 2. These  compounds are sodium class I channel blockers and are 
characterized by antiarrhythmic activity (Table 1). The second and scattered cluster form amlodipine, 
nifedipine, nimodipine, nisoldipine, nitrendipine, with positive values of factor 2 as dihydropyridine 
derivative calcium channel blockers without antiarrhythmic activity (Table 1)and belong chemically to 
4-phenyl-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate derivatives. Another cluster on the scatter 
diagram in Figure 3a comprises verapamil, amiodarone and diltiazem, with negative values of factor 1 
and factor 2, and characterized by antiarrhythmic channel blockers activity (Table 1). However, on the 
scatter diagram, the drug pentoxyphylline (with negative values of factor 1 and the most positive 
values of factor 2) is characterized only by blood vassels activity, and not classified to any of the three 
pharmacologically-related clusters proposed above.  
The positions of particular compounds on the plane determined by factors 1 and 2 obtained by 
HPLC retention data is presented in Figure 3b. On the scatter diagram, two main and close clusters 
were observed. The first cluster,  with negative values of factor 1 factor 2,  contains  nifedipine, 
nimodipine, nisoldipine, nitrendipine as 2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate 
derivatives with a  nitro-  group attached to position 2 or 3 of phenyl moiety, and  belongs 
pharmacologically to the dihydropyridine class selective calcium
  channel blockers with lack of 
antiarrhythmic activity and additionally characterized by antihypertension activity (Table 1).  The 
second cluster,  with positive values of factor 1 factor 2,  formed by diltiazem, verapamil, 
propaphenone, amlodipine and disopyramide further away, and linked compounds with sodium or 
calcium channel blockers activity and antiarrhythmic activity (exclude amlodipine with lack of 
antiarrhythmic activity), and also antihypertension activity (Table 1). However, there are two drugs, 
pentoxyphylline and amiodarone,  not classified to the two proposed main clusters. The latter 
compound belongs to α-receptors and potassium channel blockers with antiarrhythmic activity, 
whereas pentoxyphylline is characterized only by blood vassels activity. 
The position of particular compounds on the plane determined by factors 1 and 2 obtained for all 26 
parameters is presented in Figure 3c. On this scatter diagram, two main clusters are observed, however 
with some sub-clusters  showing better differentiation (similarities and dissimilarities)  in 
pharmacological features compared to the clusters presented in Figure 3a and b. The first main cluster, 
with positive values of factor 1 and negative values of factor 2, is formed by nifedipine, nimodipine, 
nisoldipine, nitrendipine, and belongs to the dihydropyridine class selective calcium
 channel blockers 
and is characterized by lack of antiarrhythmic activity (Table 1). The second main cluster, with near 0 
and negative values of factor 1, and near 0 and positive values of factor 2, is formed by diltiazem, 
verapamil, propaphenone, amlodipine, disopyramide and amiodarone, and is  characterized by 
antiarrhythmic activity (exclude amlodipine with lack of antiarrhythmic activity) (Table 1). 
Additionally, some compounds from this main cluster form other small sub-clusters containing, first, 
disopyramide and propaphenone as drugs belongs to class I sodium channel blockers, and second, 
containing diltiazem and amlodipine as calcium channel blockers (Table 1). The other small cluster 
contains  compounds verapamil and amiodarone,  belonging  to  the  class of potassium or calcium 
channel blockers as well as the class of α-receptors. 
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Figure 3. Two-dimensional scatter plots of the scores of individual drugs in the first two 
factors extracted: a) from structural parameters, b) from HPLC retention data, c) from 
structural parameters and HPLC retention data. 
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3. Materials and Methods 
3.1. Drugs 
In all experiments,  the following drugs were investigated:  amiodarone (1), diltiazem (3), 
disopyramide (4), nifedypine (5), pentoxyphylline (9), propaphenazone (10) and verapamil (11) all 
from Polpharma S.A., Starogard Gdański, Poland; amlodypine (2) from Pfizer US Pharmaceutical 
Group, New York, NY, USA; nimodypine (6), nisoldypine (7) and nitrendypine (8) all from Bayer, 
Leverkusen, Germany. 
3.2. Chromatographic Conditions 
Chromatographic analysis was performed with a Waters SM 2690 Alliance HPLC system equipped 
with  a PDA 996 diode detector (Waters Corporation, Milford, MA, USA) and Compaq Deskpro 
computer (Compaq Computer Corporation, Houston, TX, USA) with the Millennium 3.2 program for 
data collection and the process control. The following HPLC columns were employed: (a) Nucleosil 
C18 AB column, 50 × 3.0 mm i.d. (Macherey-Nagel, Düren, Germany), packed with octadecylsilica 
with particles size 5 µm; (b) IAM PC C10/C3 column, 150 × 4.6 mm i.d. (Regis Chemical Company, 
Morton Grove, IL, USA), packed with silica propylamine with the unreacted propylamine moieties 
endcapped with methylglycolate, and chemically bounded phosphatidylcholine, with particles size   
12 µm; (c) and Nucleosil 100-5 OH column, 250 × 4.0 mm i.d. (Macherey-Nagel, Düren, Germany), 
packed with silica gel with chemically bounded propanodiole, with particles size 5 µm. 
The  compounds  studied were chromatographed applying isocratic conditions  on the above 
mentioned columns at ambient temperature.  The mobile phase was acetonitrile:  Britton-Robinson 
buffer prepared at pH 2.5 and 7.0 by adding 0.2 M sodium hydroxide to a solution of 0.04 M acetic 
acid, 0.04 M phosphoric acid and 0.04 M boric acid. In the case of Nucleosil C18 AB column, the 
eluent was  used  with the following proportions 90:10, 80:20, 70:30, 60:40, 50:50, 40:60 and   
30:70 (% v/v).  However, in the case of IAM PC C10/C3 and Nucleosil 100-5 OH columns, 
experiments were performed for acetonitrile: Britton- Robinson buffer at pH 2.5 and 7.0 with the 
proportions  50:50 and 40:60 (% v/v), respectively. The detection wavelength was 254 nm. 
Additionally, all the mobile phases used in HPLC were filtered through a GF/F glass microfiber filter 
(Whatman, Maidstone, UK) and degassed by ultrasonication immediately before use. The compounds 
studied were dissolved in methanol.  
The logarithm of the HPLC retention factors (log k) for particular chromatographed compounds 
were calculated in the case of IAM PC C10/C3 and Nucleosil 100-5 OH columns, and subjected 
further to factor analysis.  In the case of Nucleosil C18 AB column, the logarithms of the HPLC 
retention  factors (log k) for particular chromatographed compounds in the given chromatographic 
system were regressed against the volume fraction of organic modifier in the eluent. The linear part of 
relationship was extrapolated to a hypothetical retention factor corresponding to 0% of organic 
modifier in the mobile phase. The resulting retention parameters were normalized to pure buffer using 
linear extrapolation and defined as log kw and subjected further to factor analysis. 
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3.3. Structural Parameters  
The structures of the tested compounds were investigated by molecular modeling with the use of 
HyperChem 7.5 software (HyperCube Inc., Gainesville, FL, USA) [23]. First, the structures of the 
compounds were pre-optimized geometrically with the molecular mechanics force field procedure 
(with MM+ method). It allowed preparing structures for further optimization steps. The resulting 
structures were optimized then by means of the quantum-based method, namely semi-empirical AM1 
method and applying the Polak-Ribiere algorithm with gradient limit of 0.01 kcal Å
−1. 
The following molecular descriptors were considered: total energy (TE), binding energy (BE), atom 
interaction energy (IAE), isolated atom energy (AIE), electronic energy (EE), core-core interaction 
energy (ECC),  heat of formation (HF), highest occupied molecular orbital energy (EHOMO) and 
lowest unoccupied molecular orbital energy (ELUMO). Moreover, electronegativity (EN) was 
calculated as an arithmetic mean of ionization potential and electron affinity according to Mulliken 
[24,25]. The “hardness” of molecules (HARD) was calculated according to Parr and Pearson [26] as 
well as Robles and Bartolotti [27] and presented as half of the difference between the ionization 
potential and the electron affinity. Additionally, the following values were used: the values of the 
highest positive (MAX_POS) and negative (MAX_NEG) charge of atoms that constitute a molecule, 
the difference between the highest positive and negative charges of atoms constituting a molecule 
(DELTA) and total dipole moment (TDM). 
Moreover, additional parameters were calculated using the QSAR Properties Module of 
HyperChem 7.5 software and include the following: surface area of the molecule available for solvent 
(SA),  volume of molecule (V), hydratation energy (HE), the logarithms of the n-octanol-water 
partition coefficient (LOG_P), refraction (R) and polarizability (P). 
3.4. Statistical Analysis 
The chemometric analysis was performed with the use of Statistica 9.0 software (StatSoft, Tulsa, 
OK, USA) with the application of principal component analysis (PCA). 
4. Conclusions 
PCA was performed for structural parameters data and HPLC retention data obtained for 11 
cardiovascular drugs. Based on the above discussion of results, the following conclusions may be 
proposed. The pattern of distribution of individual drugs on the plane determined by two principal 
components (factors 1 and 2) obtained on the basis of structural parameters, log k and log kw values 
were in good agreement with their pharmacological features. 
Moreover, PCA led to the extraction of four, three or five main factors with eigenvalue higher than 
1  from the analyzed groups  of  structural parameters, HPLC retention data or all parameters, 
respectively. The highest statistical significance were for factor 1 and factor 2. The first principle 
component (factor 1) accounted for 44-57% of variance in the data, and second principal component 
(factor 2) explained 29-33% of data variance, indicating that the total data variance that could be 
explained by the first two factors was at the level of 73-90%.  Int. J. Mol. Sci. 2010, 11                       
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From the 26 parameters used, those with the  most influence on the factor values were all the 
chromatographic parameters and some structural parameters such as total energy (TE), binding energy 
(BE), atom interaction energy (IAE), isolated atom energy (AIE), electronic energy (EE), core-core 
interaction energy (ECC),  heat of formation (HF), lowest unoccupied molecular orbital energy 
(ELUMO), the “hardness” of molecules (HARD), value of the highest positive (MAX_POS) charge of 
atoms that constitute a molecule, the difference between the highest positive and negative charges of 
atoms constituting a molecule (DELTA), surface area of the molecule available for solvent (SA), 
volume of molecule (V), the logarithms of the n-octanol-water partition coefficient (LOG_P), 
refraction (R) and polarizability (P). 
The PCA analysis proposed for application of chromatographic data together with molecular 
modeling data may help in the preliminary revision of data structure (subclasses of similar objects and 
related variables) for the studied cardiovascular system drugs as well as drug candidates according to 
similarities in their pharmacological properties. It can be used as a data compression and visualization 
method, helping finally in the proper interpretation of the received data.  
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